Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2007

Primary Completion Date

March 31, 2009

Study Completion Date

June 30, 2009

Conditions
Hepatic Encephalopathy
Interventions
DRUG

AST-120

AST-120

DRUG

lactulose

lactulose

Trial Locations (17)

10021

Weill Medical College of Cornell, New York

10029

Mount Sinai School of Medicine, New York

20010

Washington Hospital Center - MedStar Research Institute, Washington D.C.

22031

Metropolitan Research, Fairfax

23249

McGuire VA Medical Center, Richmond

30309

Digestive Healthcare of Georgia, Atlanta

35294

University of Alabama, Birmingham

44195

Cleveland Clinic Foundation, Cleveland

60637

University of Chicago, Chicago

70112

Tulane University Health Sciences Center, New Orleans

75246

Baylor University Medical Center, Dallas

77030

Baylor University Medical Center, Houston

St. Luke's Advanced Liver Therapies / St. Luke's Texas Liver Coalition - Baylor College of Medicine, Houston

90048

Cedars Sinai Medical Center, Los Angeles

92037

Scripps Clinic, San Diego

92161

Veterans Medical Center San Diego, San Diego

01655

University of Massachusetts Medical School, Worchester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ocera Therapeutics

INDUSTRY

NCT00558038 - Safety and Efficacy of AST-120 Compared to Lactulose in Patients With Hepatic Encephalopathy | Biotech Hunter | Biotech Hunter